title: Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials.
abstract: Evaluation of: Lasky JL 3rd, Panosyan EH, Plant A et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res. 33, 2047-2056 (2013). Immunotherapy for children and adults with high-grade glioma (HGG) is an emerging innovative treatment approach, which aims at stimulating the body's own immune system against HGG by using autologous dendritic cells pulsed with autologous tumor lysate as a therapeutic vaccine. This is the third report on immunotherapy for HGG in children, bringing additional knowledge and experience to the scientific community. However, at the same time, this and other manuscripts urge for the next step in treatment development.
authors.affiliation: Laboratory of Pediatric Immunology, Pediatric Neuro-Oncology, University of Leuven, Herestraat 49, 3000 Leuven, Belgium. stefaan.vangool@uzleuven.be.
authors.forename: Stefaan
authors.initials: S
authors.lastname: van Gool
mesh_terms: D001932:Brain Neoplasms / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005910:Glioma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines